The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays.
IRBM GEN Cell Imaging
This month Genetic Engineering & Biotechnology News features IRBM in an article about ‘Image-based high-content screening and predictive cell-based assays for drug discovery and development.’
The article showcases our significant experience in implementing High-Content Screening, developing disease-relevant cellular models and combining the two approaches to support integrated drug discovery research plans.
Related Posts
